Table 3.

List of FDA approvedimmunoglobulin products in infectious diseases

Product Name/ Manufacturer	Disease	Product formulation	Condition/s of disease therapy	Reference
Anthrasil (Cangene Corporation)	Anthrax	Sterile solution of purified human IgG, stabilized with 10% maltose and 0.03% polysorbate 80	Adult and pediatric patient of inhalational anthrax in combination with appropriate antimicrobial agent	https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/anthrasil
BabyBiG (California Department of Public Health)	Botulism	Sterile, lyophilized powder of IgG, stabilized with 5% sucrose and 1% human albumin	Infant botulism infected with type A and type B toxin	https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/babybig
CytoGam (Saol Therapeutics Inc)	Cytomegalovirus (CMV)	Liquid solution of IgG against CMV, stabilized by 5% sucrose and 1% Human Albumin	As a prophylactic measure to organs (kidney, lung, liver, pancreas and heart) transplant associated CMV infected patients.	https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/cytogam
HepaGam B (Cangene Corp) And Nabi-HB (Nabi Biopharmaceuticals)	Hepatitis B	Prepared from plasma donors with high-titers of anti-HBs and formulated as 5% protein solution with 10% maltose and 0.03% polysorbate 80	As apreventive agent of Hepatitis B recurrence post liver transplantation in HBsAg-positive patients.Also, as post-exposure treatment to acute HBV Infected, HepB contaminated blood exposed, infants born to HepB positive mothers	https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/hepagam-b
KEDRAB (Kamada Ltd.)	Rabies	Liquid solution of anti-rabies purified IgG immunoglobulin, stabilized with 0.3 M glycine	Post-exposure prophylaxis of rabies infected patient, given promptly after contact with rabid animal and in combination with rabies vaccine.	https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/kedrab
VariZIG (Cangene Corporation)	Varicella-zoster virus	Lyophilized preparation of purified IgG, formulated as 0.04 M sodium 197 chloride, 0.1 M glycine and 0.01% polysorbate 80	As a post-exposure prophylaxis in high risk individuals such as immunocompromised children and adults, newborns of mothers with varicella, infants below one-year age and pregnant women	https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/varizig
GamaSTAN S/D (Grifols Therapeutics Inc)	Hepatitis A Measels Rubella	Sterile solution of immunoglobulin, formulated as 15–18% protein and contains 0.21–0.32 M glycine as buffer	Used as a prophylactic measure in Hepatitis A, Measels and Rubella virus exposed person	https://www.fda.gov/media/86789/download
RespiGam (MedImmune Inc)	Respiratory Syncytial Virus (RSV)	Pooled hyperimmune polyclonal immunoglobulins from donors with high titer anti-RSV antibodies	Discontinued since 2003 due to long intravenous infusion, high dosage volume and high risk to blood borne pathogens	https://www.sec.gov/Archives/edgar/data/873591/0000873591-96-000038.txt https://www.intechopen.com/chapters/65931